Grifols, S.A. (GRFS): Price and Financial Metrics

Grifols, S.A. (GRFS): $6.56

0.09 (-1.35%)

POWR Rating

Component Grades

Momentum

C

Stability

C

Sentiment

Quality

D

Add GRFS to Watchlist
Sign Up

GRFS Price/Volume Stats

Current price $6.56 52-week high $12.15
Prev. close $6.65 52-week low $5.30
Day low $6.49 Volume 938,700
Day high $6.63 Avg. volume 3,087,432
50-day MA $7.33 Dividend yield N/A
200-day MA $8.87 Market Cap 4.51B

GRFS Stock Price Chart Interactive Chart >


Grifols, S.A. (GRFS) Company Bio


Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories. (Source:Wikipedia)


GRFS Latest News Stream


Event/Time News Detail
Loading, please wait...

GRFS Latest Social Stream


Loading social stream, please wait...

View Full GRFS Social Stream

Latest GRFS News From Around the Web

Below are the latest news stories about GRIFOLS SA that investors may wish to consider to help them evaluate GRFS as an investment opportunity.

GRFS or ZTS: Which Is the Better Value Stock Right Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Yahoo | December 27, 2023

Are You Looking for a Top Momentum Pick? Why Grifols (GRFS) is a Great Choice

Does Grifols (GRFS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Yahoo | December 14, 2023

5 Best Breakout Stocks to Invest in for Attractive Returns

Grifols (GRFS), Denison Mine Corp (DNN), NGL Energy Partners (NGL), Macatawa Bank (MCBC) and Navient (NAVI) have been selected as the breakout stocks for today.

Yahoo | December 11, 2023

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

Yahoo | December 7, 2023

Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patients

Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced the launch of its new Grifols sCD38 solution, the industry's first-ever soluble recombinant protein designed to block anti-CD38 antibodies in multiple myeloma patients receiving daratumumab therapy, ensuring quick and accurate blood transfusion tests that are critical for proper treatment.

Yahoo | November 16, 2023

Read More 'GRFS' Stories Here

GRFS Price Returns

1-mo 7.01%
3-mo N/A
6-mo -25.20%
1-year -12.88%
3-year -63.32%
5-year -64.74%
YTD -43.25%
2023 36.00%
2022 -24.31%
2021 -37.78%
2020 -20.15%
2019 28.71%

Continue Researching GRFS

Here are a few links from around the web to help you further your research on Grifols SA's stock as an investment opportunity:

Grifols SA (GRFS) Stock Price | Nasdaq
Grifols SA (GRFS) Stock Quote, History and News - Yahoo Finance
Grifols SA (GRFS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!